DT Cloud Star to merge with PrimeGen US in $1.5B SPAC deal; target advances stem cell therapy

DT Cloud Star Acquisition Corp

Deal implies ~$1.5B equity value for PrimeGen US; expected to close in H2 2026 subject to approvals.
PrimeGen's Triple Activated MSC platform targets acute liver failure; completed FDA Pre-IND meeting Dec 17, 2025.
Combined company to list on Nasdaq under a new ticker; proceeds to fund clinical development and commercialization.
Transaction requires stockholder approvals, HSR clearance, and minimum cash conditions; closing not guaranteed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.